Original Article Featured on BioTech Primer Weekly
CAR-T PRIMERThe hottest cancer therapy in the pipeline — chimeric antigen receptor therapy (CAR-T) — continued to mature in 2016 with its first FDA approval for blood cancer patients set to arrive this year.
What’s next in the world of CAR-T? A whole lot:
Additional cancer and autoimmune disease indications in preclinical development.
Added safety features.
More affordable “off the shelf” versions of the technology.
Let’s first welcome 2017 by reviewing how this key therapeutic works; we will continue our discussion by covering the future of CAR-T in our next edition.